MedPath

survey to examine the acceptability of the product Vitazyme Drops in young child to manage severe pain in the abdomen caused by wind or obstruction in the intestine characterized by high pitch crying, restlessness

Phase 4
Completed
Conditions
Health Condition 1: K598- Other specified functional intestinal disorders
Registration Number
CTRI/2019/04/018561
Lead Sponsor
East India Pharmaceutical Works Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
200
Inclusion Criteria

i.Infants & young children of both sexes aged between 1 month and 2 years.

ii.Suffering from symptoms suggestive of indigestion, flatulence, chronic constipation, persistent loose stools or poor appetite in general (as perceived by the parent) with or without colicky abdominal pain.

iii.Parent or legally acceptable representative willing to provide written informed consent.

Exclusion Criteria

i.Preterm infants (born before 37 completed weeks of gestation).

ii.Low-birth weight infants (weighing less than 2500 gms at birth).

iii.Concomitant serious medical problems including failure to thrive.

iv.Known lactose intolerance or intolerance to infant feeding formulae (baby food).

v.Suffering from diarrhoea or loose stools which could be of infectious origin.

vi.Suffering from any other symptoms suggestive of an ongoing infection.

vii.Child receiving non-permitted concomitant medication.

viii.Any other condition which in the opinion of the investigator is not conducive towards inclusion of the subject in the study.

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
i.Improved digestion & flatulence â?? as judged by the absence of excessive regurgitation, hiccups, belching / eructation, abdominal distension, excessive flatulence, nausea, vomiting. <br/ ><br>ii.Increase in colic-free periods â?? as judged by a reduction in mean daily crying time, particularly during the night.Timepoint: 3 visits in a complete study
Secondary Outcome Measures
NameTimeMethod
safetyTimepoint: In case of Adverse Event unscheduled visit at any time in the study duration
© Copyright 2025. All Rights Reserved by MedPath